Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Judy Muldawer who wrote (6029)	2/4/1999 10:48:00 AM
From: Henry Niman	of 6136

Judy, Speaking of AGPH, LGND, and BioCognizance, VRTX came out with a press release on Agenerase indicating that it did not affect lipid metabolism and retinoid signaling, although three PIs including Vircept did. Assays were in vitro and looked at PPARs and RXRs in addition to lipid metabolism. WLA of course has Rezulin which is a TZD that activates PPARs and they have an alliance with AGN that targets RXRs. The work was done by GLX, who of course had an alliance with LGND to look at lipid metabolism via PPAR/RXR signaling. The experiments used LGND's rexinoid, Targretin as wells as AGN's anti-retinoid. Details are linked to the anti-HIV page under New Therapeutics at biocognizance.com Thus, there could be some interesting intersections between PIs (represented by AGPH's Viracept) and lipid metabolism (represented by WLA's TZD, Rezulin, and AGN's rexinoids).

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next